Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy (Q36623633)

15 August 2017

1 reference

title

Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy (English)

1 reference

15 August 2017

Kim R

1

1 reference

15 August 2017

Emi M

series ordinal

2

1 reference

15 August 2017

Matsuura K

series ordinal

3

1 reference

15 August 2017

Tanabe K

series ordinal

4

1 reference

15 August 2017

13 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

14

1 reference

15 August 2017

1

1 reference

15 August 2017

1-11

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700986

15 August 2017

0 references

cites work

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Bcl-2 and apoptosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

The role of the Bcl-2 protein family in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Bcl-2 antisense therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Mitochondria: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Mitochondria: A novel target for the chemoprevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Recent advances in understanding the cell death pathways activated by anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Mitochondria: pharmacological manipulation of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Targeted therapy against Bcl-2-related proteins in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Antisense strategies for oncogene inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Pharmacological manipulation of Bcl-2 family members to control cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Structural and biochemical basis of apoptotic activation by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Molecular characterization of mitochondrial apoptosis-inducing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Caspase-dependent and -independent death pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Autophagy in cell death: an innocent convict?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

The pleiotropic role of autophagy: from protein metabolism to bactericide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Induction of autophagy and inhibition of tumorigenesis by beclin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Immature myeloid cells and cancer-associated immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Bax directly induces release of cytochrome c from isolated mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

Involvement of the bcl-2 gene in human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

7 January 2021

Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

7 January 2021

Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

7 January 2021

IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

7 January 2021

Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700986

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700986

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference